![Galderma logo black](/sites/default/files/Galderma_Logo.png)
26 . 10 .2023
Press release
Galderma phase III data published in The New England Journal of Medicine: full Olympia 2 trial results demonstrate nemolizumab’s rapid onset of action in patients with prurigo nodularis
![LQD 2023](/sites/default/files/Rectangle%2090_0.jpg)
13 . 10 .2023
Press release
Galderma unveils bold ambition in neuromodulation at Liquid Live event
![EADV 2023 Nemo](/sites/default/files/Thumbnail_EADV2023_LateBreaker.png)
11 . 10 .2023
Press release
Galderma @ EADV 2023: phase III trials demonstrate nemolizumab’s efficacy and rapid onset of action in atopic dermatitis and prurigo nodularis
![EADV 2023](/sites/default/files/Curtain%20Raiser%20Website_release.png)
04 . 10 .2023
Press release
EADV 2023: Galderma to present new data showcasing its continued leadership in dermatology
![Dr Mara Weinstein](/sites/default/files/CAPA11%20Galderma%20Dr.%20Mara%20Weinstein%20Velez0131%20DSC_7506.jpg.jpg)
03 . 10 .2023
News story
“A product for any type of skin”: celebrating Cetaphil’s range and reliability
![](/sites/default/files/Alastin_Publication_assets_Galderma.com.png)
02 . 10 .2023
News story
Alastin Skincare: Galderma announces launch in the UK and direct distribution and expansion in Canada
![Galderma logo](/sites/default/files/Galderma%20logo_BlackBackground_700x525.png)
02 . 10 .2023
Press release
Galderma announces progress with RelabotulinumtoxinA regulatory submissions
![Alastin C-RADICAL Defense Antioxidant Serum](/sites/default/files/Press_opt2.png)
14 . 09 .2023
Press release
Galderma launches advanced new serum with ALASTIN Skincare® - C-RADICAL Defense Antioxidant Serum